European Medicines Agency (EMA)

EU agency

European Medicines Agency, an EU medicines regulator · European Union

Visit the source site · Audited 2026-10-14

Who pays for it

EMA's 2025 final budget was €600.23 million, with 91.4% of income from the broad category of medicine evaluation and related activities, 8.3% from the EU budget, and 0.3% from other sources; its 2026 page estimates 91.5%, about €563.2 million, from fees and charges.

Status: Labeled

EMA is labeled as an EU regulator because it relies heavily on regulatory fees. Its public assessments and expert declarations are useful, but it is cited with an independent check, not alone.

How SafeMomma uses it

We use EMA assessments and product information within their stated scope, with a source from a different owner for consequential claims and a separate check of pregnancy or breastfeeding relevance.

The audit

Who controls it: EMA opinions come from specialist committees and the European medicines regulatory network; applicants submit dossiers, while the European Commission or national authorities make formal authorization decisions. PRAC includes Member State and EEA representatives, six Commission-appointed independent experts, and patient and healthcare-professional representatives.
Money: The 2025 income category for medicine evaluation and related activities was 91.4%, a broad category that is not all direct industry fees. The EU budget supplied 8.3% and other sources 0.3%; EMA's 2026 page estimates 91.5% from fees and charges.
Conflict rules: EMA publishes committee members' CVs and conflict declarations, with procedures to identify and restrict participation where interests conflict. The reviewed material did not show a separate conflict statement on every page.
Method: EMA publishes European Public Assessment Reports, public summaries, committee assessment reports, and product information. Clinical data submitted for centrally reviewed medicine applications have been published under EMA policy since October 2016, with account access, terms, and possible redactions; herbal monographs distinguish established use from traditional use.
Dates on its pages: Product assessment reports and herbal-product pages have individual dates and statuses, and no portfolio-wide median age was reported.
Political exposure: EMA operates under EU law and governance, where budgets, mandates, and authorization rules can change. In materials reviewed for 2015 to 2026, no source-specific political order to rewrite an EMA assessment or remove a sampled page was identified; this was not an exhaustive historical search.
Money exposure: The 2025 broad income category and the 2026 fee estimate show structural reliance on regulated medicines and services. The reviewed evidence did not show that a fee payer directed a particular committee conclusion.
Track record: Across backtests b1 to b5, EMA issued dated valproate restrictions in 2014 and 2018, topiramate pregnancy-prevention measures in 2023, an ondansetron label-change recommendation in 2019 after a separate information request, and unchanged EU paracetamol advice in 2025 and 2026. Its topiramate summary noted inconsistent neurodevelopment findings and substantially overlapping Nordic datasets; the codeine review recorded EMA's 2013 breastfeeding contraindication wording, distinct from FDA's wording. The ondansetron and codeine backtests found no source-specific evidence that political or financial pressure changed EMA wording.

Where this comes from

Incentive exposure describes pressure from money or politics, not whether the source is right. Funding alone does not show influence.

← Back to Our sources